Cargando…
High tumor amplification burden is associated with TP53 mutations in the pan-cancer setting
Next-generation sequencing data is fundamentally changing the clinical management of patients with cancer. The most frequent genomic alterations in malignancy are mutations and amplifications, with a subset of tumors having multiple amplifications – “amplificators”. We sought to understand the molec...
Autores principales: | Joshi, Rushikesh S., Boichard, Amelie, Adashek, Jacob J., Kurzrock, Razelle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542347/ https://www.ncbi.nlm.nih.gov/pubmed/36171565 http://dx.doi.org/10.1080/15384047.2022.2128608 |
Ejemplares similares
-
Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues
por: Li, Alex M., et al.
Publicado: (2019) -
Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy
por: Pham, Timothy V., et al.
Publicado: (2020) -
Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden
por: Boichard, Amélie, et al.
Publicado: (2021) -
High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations
por: Boichard, Amélie, et al.
Publicado: (2017) -
Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden
por: Bieg‐Bourne, Cheyennedra C., et al.
Publicado: (2020)